Company Description
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients.
The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.
The company’s pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28.
The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026.
The company was incorporated in 1999 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 1999 |
| IPO Date | Feb 4, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Anand Parikh |
Contact Details
Address: 1405 Research Boulevard, Suite 125 Rockville, Maryland 20850 United States | |
| Phone | 240 243 8000 |
| Website | faeththerapeutics.com |
Stock Details
| Ticker Symbol | FTH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001829802 |
| CUSIP Number | 81728A207 |
| ISIN Number | US81728A2078 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Anand Parikh | Chief Executive Officer |
| Brian Stephenson | Chief Financial Officer |
| Anand Parikh | Chief Operating Officer |
| Lora Pike | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2026 | SCHEDULE 13G | Filing |
| Jun 23, 2026 | SCHEDULE 13G | Filing |
| Jun 18, 2026 | 8-K | Current Report |
| Jun 18, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Jun 15, 2026 | 8-K | Current Report |
| Jun 12, 2026 | EFFECT | Notice of Effectiveness |
| Jun 10, 2026 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Jun 10, 2026 | 8-K | Current Report |
| Jun 3, 2026 | SCHEDULE 13G/A | Filing |
| Jun 2, 2026 | 10-K/A | [Amend] Annual report |